<!doctype html>
<html lang="en">

<head>
  <!-- Required meta tags -->
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

  <!-- Bootstrap CSS -->
  <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.0/css/bootstrap.min.css" integrity="sha384-9aIt2nRpC12Uk9gS9baDl411NQApFmC26EwAOH8WgZl5MYYxFfc+NcPb1dKGj7Sk" crossorigin="anonymous">

  <!-- Other CSS -->
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;0,800;1,300;1,400;1,600;1,700;1,800&display=swap">
  <link rel="stylesheet" href="bchu.css">
  <link rel="icon" href="images/penn-favicon.png" type="image/x-icon">
  <title>Antimicrobial Stewardship</title>
</head>


<body>

  <header class="header-penn">
    <!-- NAVBAR -->
    <nav class="navbar navbar-expand-lg navbar-dark navbar-penn">
      <a class="navbar-brand logo-penn" href="#">
        <img src="images/penn-shield.png" width="30" height="30" class="d-inline-block align-center">
        Penn Med Antimicrobial Stewardship
      </a>
      <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
        <span class="navbar-toggler-icon"></span>
      </button>
      <div class="collapse navbar-collapse" id="navbarNav">
        <div class="navbar-nav">
          <a href="#" class="nav-item nav-link ml-4">Home</a>
          <a href="#" class="nav-item nav-link ml-4">Microbiology (Bugdrug)</a>
          <a href="#" class="nav-item nav-link ml-4">ID Transition Service (IDTS)</a>
          <a href="#" class="nav-item nav-link ml-4">Education</a>
          <a href="#" class="nav-item nav-link ml-4">Contact Us</a>
        </div>
      </div>
    </nav>
  </header>

  <div class="container site-content">
    <div class="row">

      <!-- aside for SIDEBAR -->
      <aside class="col-12 col-lg-3">
        <div class="nav-div-penn">
          <nav class="nav flex-column nav-penn">
            <a href="#" class="nav-link">Home</a>
            <a class="nav-link" href="#">ilum</a>
            <a class="nav-link" href="#">Antibiotic Approval</a>
            <div class="dropdown">
              <a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#" role="button" aria-haspopup="true" aria-expanded="false">Treatment Guidelines</a>
              <div class="dropdown-menu" aria-labelledby="dropdownMenuLink">
                <a class="dropdown-item" href="#">Abdominal Infections</a>
                <a class="dropdown-item" href="#">Bone and Joint Infections</a>
                <a class="dropdown-item" href="#">Candida Empiric Treatment Guidelines</a>
                <a class="dropdown-item" href="#">Central Nervous System Infections</a>
                <a class="dropdown-item" href="#">COVID-19 Infection</a>
                <a class="dropdown-item" href="#">Endocarditis</a>
                <a class="dropdown-item" href="#">Gastroenteritis</a>
                <a class="dropdown-item" href="#">Genitourinary Infections</a>
                <a class="dropdown-item" href="#">Gynecologic and Obstetrics Guidelines</a>
                <a class="dropdown-item" href="#">Neutropenic Fever</a>
                <a class="dropdown-item" href="#">Respiratory Tract Infections</a>
                <a class="dropdown-item" href="#">Sepsis</a>
                <a class="dropdown-item" href="#">Skin and Soft Tissue</a>
              </div>
            </div>
            <a class="nav-link" href="#">Prophylaxis Guidelines</a>
            <a class="nav-link" href="#">Antimicrobial Dosing</a>
            <a class="nav-link" href="#">Antimicrobial Information</a>
            <a class="nav-link" href="#">Antimicrobial Formulary</a>
          </nav>
        </div>
      </aside>

      <!-- article contains the accordion, CSS means 12 mobile, 9 when lg -->
      <article class="col-12 col-lg-9">
        <h1>Penn Med COVID-19 Guidelines</h1>

        <div class="card mb-4">
          <div class="card-header">
            Updates at a Glance
          </div>
          <div class="card-body">
            <div class="card-subtitle">Emerging literature</div>
            <p class="card-text">Following a study run by the National Institutes of Health, an initial Data Safety Monitoring Board analysis revealed that <b>remdesivir</b> was associated with decreased time to recovery from 15 to 11 days when compared to placebo, but did not have a statistically significant decrease in mortality.</p>
            <div class="card-subtitle">New Guidelines</div>
            <p class="card-text"><b>Remdesivir</b> has been approved via an Emergency Use Authorization (EUA) by the Food and Drug Administration. Hospitals have been allocated only several treatment courses of the medication at this time; however, this amount is expected to increase over the next month.<br> <a href="#">Penn Medicine Remdesivir Emergency Use Authorization Guidelines</a></p>
            <div class="card-subtitle">Other Key Information</div>
            <p class="card-text"><a href="#">Penn guidelines to help with the triage, work-up, and disposition management of patients with COVID-19</a><br><a href="#">Penn guidelines for prophylactic and therapeutic anticoagulation in inpatients with COVID-19 (available only on Penn Medicine networks)</a></p>
          </div>
        </div>

        <!-- accordion -->
        <div class="accordion" id="abdominal">
          <div class="card">
            <div class="card-header" id="headingOne">
              <h2 class="mb-0">
                <button class="btn btn-link btn-penn" type="button" data-toggle="collapse" data-target="#collapseOne" aria-expanded="true" aria-controls="collapseOne"><i class="fa fa-plus"></i>
                  Medication-Specific Evidence Review
                </button>
              </h2>
            </div>
            <!--  To show by default, add "show" to the class of id=collapseOne  -->
            <div id="collapseOne" class="collapse" aria-labelledby="headingOne" data-parent="">
              <div class="card-body">
                <ul>
                  <li><a href="#">ACE Inhibitors and Angiotensin Receptor Blockers</a></li>
                  <li><a href="#">Azithromycin</a></li>
                  <li><a href="#">Baricitinib</a></li>
                  <li><a href="#">BCG</a></li>
                  <li><a href="#">Chloroquine</a></li>
                  <li><a href="#">Convalescent Plasma</a></li>
                  <li><a href="#">Corticosteroids</a></li>
                  <li><a href="#">Favipiravir</a></li>
                  <li><a href="#">Hydroxychloroquine</a></li>
                  <li><a href="#">Hydroxychloroquine vs. Chloroquine</a></li>
                  <li><a href="#">Interferon</a></li>
                  <li><a href="#">Intravenous Immunoglobulin</a></li>
                  <li><a href="#">Lopinavir-ritonavir</a></li>
                  <li><a href="#">NSAIDs</a></li>
                  <li><a href="#">Oseltamivir</a></li>
                  <li><a href="#">Proton Pump Inhibitors</a></li>
                  <li><a href="#">Remdesivir</a></li>
                  <li><a href="#">Ribavirin</a></li>
                  <li><a href="#">Statins</a></li>
                  <li><a href="#">Tocilizumab</a></li>
                  <li><a href="#">Zinc</a></li>
                </ul>
              </div>
            </div>
          </div>
          <div class="card">
            <div class="card-header" id="headingTwo">
              <h2 class="mb-0">
                <button class="btn btn-link collapsed btn-penn" type="button" data-toggle="collapse" data-target="#collapseTwo" aria-expanded="false" aria-controls="collapseTwo"><i class="fa fa-plus"></i>
                  Treatment Guidelines for Laboratory-Confirmed COVID-19
                </button>
              </h2>
            </div>
            <div id="collapseTwo" class="collapse" aria-labelledby="headingTwo" data-parent="">
              <div class="card-body">
                <p class="card-text">An Infectious Diseases consultation is <b>not necessary</b> for all patients admitted to the hospital with COVID-19, but should be considered in patients with:

                </p>
                <ul>
                  <li>Critical illness including acute respiratory distress syndrome, shock, or cytokine-activation syndrome</li>
                  <li>Pregnancy</li>
                  <li>Immunocompromising conditions, including but not limited to, poorly controlled HIV infection, history of solid-organ transplantation, history of bone marrow transplantation, rheumatologic disease on immuno-modulator therapy, and hematologic malignancy</li>
                  <li>Positive testing or concern for co-infections, including viral, bacterial, or fungal</li>
                  <li>Negative testing for SARS-CoV-2 but with a high clinical suspicion for COVID-19</li>
                </ul>
                <p class="card-text"><a href="#">Triage, Work-up, and Disposition Management of Patients with COVID-19</a></p>
                <p class="card-text"><a href="#">Prophylactic and Therapeutic Anticoagulation in Inpatients with COVID-19 (available only on Penn servers)</a></p>
                <p class="card-text">Antibacterial therapy consistent with Community-Acquired Pneumonia Treatment Guidelines, Ventilator/Hospital-Associated Pneumonia Treatment Guidelines, and/or Sepsis Treatment Guidelines should be initiated promptly in critically ill patients with sepsis with acute end-organ dysfunction or shock.</p>
                <p class="card-text">Procalcitonin can be checked in cases where antibacterial therapy is considered and sequential procalcitonin measurements can be made if initial procalcitonin is elevated to help guide decision making on continuation of antibacterial therapy. Procalcitonin results should be interpreted in the context of the clinical picture.</p>
                <p class="card-text">If ACE inhibitors, ARBs, and NSAIDs are clinically indicated, they can be continued based on available data</p>
                <p class="card-text"><a href="#">Algorithm for QT Monitoring in Patients with COVID-19 on potential QT-prolonging medications</a></p>
                <p class="card-text">These guidelines reflect our best medical judgment based on current knowledge about a novel virus and are subject to change as additional information becomes available. The purpose of this document is to serve as a guide for optimal care; not as a substitute for clinical judgment</p>
                <div class="table-responsive">
                  <table class="table table-sm table-penn">
                    <thead class="thead-penn">
                      <tr>
                        <th scope="col">Treatment Considerations</th>
                        <th scope="col">Clinical Trial Considerations</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="2" class="tr-penn"><strong>Non-hospitalized patients</strong></td>
                      </tr>
                      <tr>
                        <td>Symptomatic treatment and monitoring are preferred.</td>
                        <td>Patients being recruited from Penn Medicine testing sites for hydroxychloroquine trial<sup>1</sup></td>
                      </tr>
                      <tr>
                        <td class="tr-penn" colspan="2"><strong>Hospitalized patients with mild illness</strong><br>Pulse oximetry &gt;94% and no supplemental oxygen (non-pregnant)</td>
                      </tr>
                      <tr>
                        <td>Symptomatic treatment and supportive care are preferred.</td>
                        <td>Consider referring for clinical trial or expanded access with <b>remdesivir plus baricitinib</b> or remdesivir plus placebo<sup>2</sup> if patient qualifies</td>
                      </tr>
                      <tr>
                        <td class="tr-penn" colspan="2"><strong>Hospitalized patients with severe illness</strong><br>Pulse oximetry &le;94% or need for supplemental oxygen who are not intubated (non-pregnant)</td>
                      </tr>
                      <tr>
                        <td>Consider EUA <b>remdesivir for 5 days</b> if patient eligible. <br><a href="#">Penn Medicine Remdesivir EUA Guidelines</a></td>
                        <td>Consider referring for clinical trial with <b>remdesivir plus baricitinib</b> or remdesivir plus placebo<sup>2</sup> or clinical trial or expanded access with <b>convalescent plasma</b><sup>3</sup> if patient qualifies</td>
                      </tr>
                      <tr>
                        <td class="tr-penn" colspan="2"><strong>Critically-ill and intubated</strong><br>(non-pregnant)</td>
                      </tr>
                      <tr>
                        <td>
                          <p>
                            Consider EUA <b>remdesivir for 5-10 days</b> if patient eligible. If a patient starts on remdesivir and is intubated later, treatment duration can be extended to 10 days if clinically warranted. <a href="#">Penn Medicine Remdesivir EUA Guidelines</a>
                          </p>
                          <p><b>Corticosteroids</b> have mixed data with some studies suggesting potential improvement in ARDS and others suggesting worse outcomes and prolonged viral shedding. <b>Corticosteroids are recommended in patients with compelling indications including patients with refractory septic shock and obstructive lung disease</b>. Corticosteroids can be considered in patients with ARDS when potential benefits outweigh risks and after discussion with infectious diseases and pulmonary.</p>
                          <p>Antibacterial therapy consistent with <a href="#">Community-Acquired Pneumonia Treatment Guidelines</a>, <a href="#">Ventilator/Hospital-Associated Pneumonia Treatment Guidelines</a>, and/or <a href="#">Sepsis Treatment Guidelines</a> should be initiated promptly in critically ill patients with sepsis with acute end-organ dysfunction or shock.</p>
                        </td>
                        <td>Consider referring for clinical trial with <b>remdesivir plus baricitinib</b> or remdesivir plus placebo<sup>2</sup> or clinical trial or expanded access with <b>convalescent plasma</b><sup>3</sup> if patient qualifies</td>
                      </tr>
                      <tr>
                        <td class="tr-penn" colspan="2"><strong>Pregnant patient with hospital admission for COVID-19 </strong></td>
                      </tr>
                      <tr>
                        <td>
                          <p>Consider treatment with:
                            Supportive care and symptomatic treatment
                            <b>OR</b>
                            Compassionate use Remdesivir 200 mg IV x 1 day then 100 mg IV daily for total 10-14 days<sup>4</sup>; safety data of remdesivir in pregnant humans are limited so decision to use remdesivir should be made in conjunction with Maternal Fetal Medicine and Infectious Diseases as well as shared decision making with the patient.</p>
                          <p>Betamethasone 12mg IM Q24H x 2 doses for fetal lung maturity may be considered in cases at very high risk of preterm delivery before 34 weeks. These cases should be reviewed with Maternal Fetal Medicine prior to administration of betamethasone.</p>
                        </td>
                        <td>Not applicable</td>
                      </tr>

                    </tbody>
                  </table>
                </div>
                <div class="table-subtext">
                  <p>
                    <sup>1</sup>Patients are being prospectively identified at the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center if they fit eligibility criteria for hydroxychloroquine trial. Principal investigators are Ravi Amaravadi, Benjamin Abella, and Ian Frank.
                  </p>
                  <p>
                    <sup>2</sup>If you think a patient would qualify for a remdesivir trial and you do not need a formal Infectious Diseases consultation, please message the Cureatr pool called “Remdesivir and Convalescent Plasma Clinical Trials”. If there are any problems, reach out to Pablo Tebas (HUP) or William Short (PPMC) rather than paging the Infectious Diseases fellow (find contact information in UPHS phone book). Do not alter patient treatment or testing based on the possibility of trial enrollment. If a patient is enrolled, the trial team will notify you of any necessary changes. The inclusion and exclusion criteria for possible trials are listed below. Just because a patient fits inclusion criteria does not mean that the patient can be enrolled in a clinical trial with remdesivir because trial enrollment depends on active enrollment and remdesivir availability. These trials are available only if the patient is an inpatient at Hospital of the University of Pennsylvania or Penn Presbyterian Medical Center.
                  </p>
                  <p class="table-subtext-table">
                     <a class="btn btn-outline-primary btn-block collapsed" data-toggle="collapse" href="#collapseTable1" role="button" aria-expanded="false" aria-controls="collapseTable1">
                      Adaptive COVID-19 Treatment Trial Criteria
                    </a>
                  </p>
                  <div class="collapse" id="collapseTable1">
                    <div class="table-responsive">
                      <table class="table table-sm table-penn">
                        <thead class="thead-penn">
                          <tr>
                            <th scope="col">
                              Adaptive COVID-19 Treatment Trial (ACTT)
                              Remdesivir (10 days) + Baricitinib (14 days) vs. Remdesivir (10 days) + Placebo (14 days)</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td class="inclusion">
                              Inclusion Criteria:
                              <ul>
                                <li>Admitted to the hospital with Covid-19</li>
                                <li>Male or non-pregnant female adults &ge;18 years at time of enrollment</li>
                                <li>Laboratory confirmed SARS-CoV-2 infection determined by PCR &lt;72 hours prior to randomization</li>
                                <li>Illness of any duration, including mechanical ventilation and ECMO</li>
                              </ul>
                            </td>
                          </tr>
                          <tr>
                            <td class="exclusion">
                              Exclusion Criteria:
                              <ul>
                                <li>ALT or AST &gt;5 times the upper limit of normal</li>
                                <li>eGFR &lt;30 ml/min or hemodialysis or hemofiltration</li>
                                <li>Neutropenia (ANC &lt;1000)</li>
                                <li>Lymphopenia (ALC &lt;200)</li>
                                <li>Creatinine clearance &lt; 50</li>
                                <li>Pregnancy or breastfeeding</li>
                                <li>Anticipated discharge within 72 hours</li>
                                <li>Allergy to study medication(s)</li>
                                <li>Received cytotoxic or biologic treatment within 4 weeks prior to screening</li>
                                <li>Received TNF inhibitor within 2 weeks prior to screening</li>
                                <li>Received convalescent plasma or IVIG for COVID-19</li>
                                <li>Has received corticosteroids at high dose (Prednisone &gt;10mg/day or equivalent) within 2 weeks of screening (will be amended soon)</li>
                                <li>Use of probenecid that cannot be discontinued</li>
                                <li>Diagnosis of current active TB or latent TB with &lt;4 weeks of treatment</li>
                                <li>Suspected serious active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator would constitute a risk</li>
                                <li>Has received a live vaccine (live attenuated) within 4 weeks of screening</li>
                                <li>History of DVT, PE within 12 weeks prior to screening or has a history of recurrent (&gt;1) DVT/PE</li>
                              </ul>
                            </td>
                          </tr>
                        </tbody>
                      </table>
                    </div>
                  </div>
                  <p>
                    <sup>3</sup>Convalescent plasma can be accessed through an expanded access protocol by Mayo Clinic (see below) or patients may be referred to a clinical trial at the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center:
                  </p>
                  <p class="table-subtext-table">
                     <a class="btn btn-outline-primary btn-block collapsed" data-toggle="collapse" href="#collapseTable2" role="button" aria-expanded="false" aria-controls="collapseTable2">
                      Convalescent Plasma Protocol and Trial Criteria
                    </a>
                  </p>
                  <div class="collapse" id="collapseTable2">
                    <div class="table-responsive">
                      <table class="table table-sm table-penn">
                        <thead class="thead-penn">
                          <tr>
                            <th scope="col">Mayo Clinic Convalescent Plasma Expanded Access </th>
                            <th scope="col">University of Pennsylvania Convalescent PlasmaTrial</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td>
                              <p>Sites: Penn Medicine Princeton Medical Center (PMPMC), Pennsylvania Hospital (PAH), and Lancaster General Hospital (LGH)</p>
                              <p>Contact: Contact Infectious Diseases for availability</p><a href="#">Website</a>
                            </td>
                            <td>
                              <p>Sites: Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center</p>
                              <p>Contact: To evaluate for eligibility, enter request in Cureatr to the “Remdesivir and Convalescent Plasma” pool; PI: Katherine Bar</p>
                            </td>
                          </tr>
                          <tr>
                            <td class="inclusion">Inclusion Criteria
                              <ul>
                                <li>Age &ge;18 years</li>
                                <li>Laboratory confirmed diagnosis of SARS-CoV-2</li>
                                <li>Admitted to an acute care facility for the treatment of COVID-19 complications</li>
                                <li>Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease</li>
                                <li>Informed consent provided by the patient or healthcare proxy</li>
                              </ul>
                              <p>
                                Severe COVID-19 is defined by one or more of the following: (1) Dyspnea; (2) Respiratory frequency &ge;30/min; (3) Blood oxygen saturation &le;93%; (4) Partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt;300; (5) Lung infiltrates &gt;50% within 24-48 hours
                              </p>
                              <p>
                                Life-threatening COVID-19 is defined as one or more of the following: (1) Respiratory failure; (2) Septic shock; (3) Multiple organ dysfunction or failure
                              </p>
                            </td>
                            <td class="inclusion">
                              Inclusion Criteria CCP1 (all receive plasma):
                              <ul>
                                <li>Age &ge;18 years</li>
                                <li>Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other authorized or approved assay in any specimen collected within 72 hours prior to enrollment</li>
                                <li>Hospitalized, intubated, and mechanically ventilated in an intensive care unit</li>
                                <li>Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g., chest x-ray or CT scan)</li>
                                <li>Patient or proxy is willing and able to provide written informed consent and comply with all protocol requirements</li>
                              </ul>
                              Inclusion Criteria CCP2 (randomized 1:1 to plasma + standard care vs. standard care alone):
                              <ul>
                                <li>Age &ge;18 years</li>
                                <li>Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other authorized or approved assay in any specimen collected within 72 hours prior to enrollment</li>
                                <li>Hospitalized in any participating facility</li>
                                <li>Abnormal respiratory status documented at any point within 24 hours prior to randomization, defined as: room air saturation of oxygen (SaO2) &lt;93%, OR requiring supplemental oxygen, OR tachypnea with respiratory rate &ge;30</li>
                                <li>Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g. chest x-ray or CT scan)</li>
                                <li>Patient or proxy is willing and able to provide written informed consent and comply with all protocol requirements</li>
                              </ul>
                            </td>
                          </tr>
                          <tr>
                            <td class="exclusion">No exclusion criteria</td>
                            <td class="exclusion">Exclusion Criteria:
                              <ul>
                                <li>Contraindication to transfusion (e.g. severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator</li>
                                <li>Clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than COVID-19</li>
                                <li>Receipt of other investigational therapy for the treatment of the COVID-19 as a part of another clinical trial or prior enrollment</li>
                              </ul>
                            </td>
                          </tr>
                        </tbody>
                      </table>
                    </div>
                  </div>
                  <p>
                    <sup>4</sup>Compassionate use remdesivir is not an FDA-approved medication and should be obtained only through infectious diseases consultation. It requires Institutional Review Board (IRB) approval. <a href="https://rdvcu.gilead.com">Application for use</a>. <a href="https://docs.google.com/presentation/d/1RKYAY-m8TfEHqBvcsYduGhjmc3uhh0A1mZleqk8lTnQ/edit#slide=id.g7293329568_0_51">Step-by-step instructions to apply for compassionate use remdesivir</a>. Inclusion criteria are confirmed SARS-CoV-2 by PCR and mechanical ventilation. Exclusion criteria include, evidence of multi-organ failure, pressor requirement, ALT levels &gt;5 times upper limit of normal, or creatinine clearance &lt;30 mL/min or dialysis or continuous veno-venous hemofiltration. At this time the only available compassionate use indication for adults is in pregnant women. An expanded access program for other indications is likely forthcoming in the near future.
                  </p>
                </div>
              </div>
            </div>
          </div>
          <div class="card">
            <div class="card-header" id="headingThree">
              <h2 class="mb-0">
                <button class="btn btn-link collapsed btn-penn" type="button" data-toggle="collapse" data-target="#collapseThree" aria-expanded="false" aria-controls="collapseThree"><i class="fa fa-plus"></i>
                  Additional Treatment Considerations in Patients with COVID-19 and Solid Organ Transplantation (SOT)
                </button>
              </h2>
            </div>
            <div id="collapseThree" class="collapse" aria-labelledby="headingThree" data-parent="">
              <div class="card-body">
                <div class="table-responsive">
                  <table class="table table-sm table-penn">
                    <thead class="thead-penn">
                      <tr>
                        <th scope="col">Recommendation</th>
                        <th scope="col">Notes</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="2" class="tr-penn"><strong>IgG &lt;400</strong></td>
                      </tr>
                      <tr>
                        <td>Please consult the Transplant Infectious Diseases team if IVIG is being considered.</td>
                        <td>Major adverse events: venous thromboembolism, infusion-related reaction, acute kidney injury</td>
                      </tr>
                      <tr>
                        <td colspan="2" class="tr-penn"><strong>All Solid Organ Transplant Recipients</strong></td>
                      </tr>
                      <tr>
                        <td>
                          <p><b>Outpatient:</b> All notifications of transplant patients who are not currently inpatient (including those not seen inpatient but require follow-up) should be routed to: <a href="transplantinfectiousdiseases_covid@pennmedicine.upenn.edu">transplantinfectiousdiseases_covid@pennmedicine.upenn.edu</a></p>
                          <p><b>Inpatient:</b> All patients with SpO2 &le;94%:
                            Consider EUA remdesivir for 5-10 days if patient eligible and drug is available. <a href="#">Penn Medicine Remdesivir Emergency Use Authorization Guidelines</a></p>
                          <p>The Transplant Infectious Diseases team should be notified of all admitted SOT recipients with confirmed COVID-19 within 24 hours of admission. SOT recipients with confirmed COVID-19 and any of the following should be admitted to one of the COVID-specific services: hypoxia (SpO2 &lt;94% on room air), radiographic evidence of pneumonia, or evidence of end-organ damage (acute kidney injury, acute liver injury, etc.). SOT recipients who do not meet any of the above criteria AND have a reliable follow-up plan may be discharged home. For any SOT recipient who is discharged home, the ED provider should send a secure message to the patient’s transplant coordinator AND either the patient’s transplant infectious disease physician (if there is one on record) or the transplant infectious diseases attending on service.</p>
                        </td>
                        <td>Consider clinical trials if patient is eligible (see above)</td>
                      </tr>
                      <tr>
                        <td colspan="2" class="tr-penn"><strong>Kidney/Kidney-Pancreas, Liver/Liver-Kidney, Heart/Heart-Liver</strong></td>
                      </tr>
                      <tr>
                        <td>
                          <p><b>Asymptomatic:</b>
                            Close monitoring
                          </p>
                          <p><b>All patients with SpO2 &le;94%:</b>
                            Consider EUA remdesivir for 5-10 days if patient eligible and drug is available. <a href="#">Penn Medicine Remdesivir Emergency Use Authorization Guidelines</a></p>
                          <p><b>Mild-moderate disease (i.e. shortness of breath/hypoxia but SpO2 &gt;90% on nasal cannula):</b>
                            Consider reducing or withholding cell cycle inhibitor (e.g. mycophenolate, azathioprine), if deemed appropriate by Transplant service</p>
                          <p><b>Severe disease (i.e. extensive PNA and/or respiratory failure requiring ICU admission):</b>
                            Consider withholding cell cycle inhibitor (e.g. mycophenolate, azathioprine) or other modification in immunosuppression if deemed appropriate by Transplant service</p>
                        </td>
                        <td>Consider clinical trials if patient is eligible (see above)</td>
                      </tr>
                      <tr>
                        <td colspan="2" class="tr-penn"><strong>Lung</strong></td>
                      </tr>
                      <tr>
                        <td><b>All patients with SpO2 &le;94%:</b>
                          Consider EUA remdesivir for 5-10 days if patient eligible and drug is available. <a href="#">Penn Medicine Remdesivir Emergency Use Authorization Guidelines</a></td>
                        <td>Consider clinical trials if patient is eligible (see above)</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div>
            </div>
          </div>
          <div class="card">
            <div class="card-header" id="headingFive">
              <h2 class="mb-0">
                <button class="btn btn-link collapsed btn-penn" type="button" data-toggle="collapse" data-target="#collapseFive" aria-expanded="false" aria-controls="collapseFive"><i class="fa fa-plus"></i>
                  Prophylaxis after SARS-CoV-2 Exposure
                </button>
              </h2>
            </div>
            <div id="collapseFive" class="collapse" aria-labelledby="headingFive" data-parent="">
              <div class="card-body">
                <p>We do not recommend routine post-exposure prophylaxis. If signs/symptoms develop, follow treatment guidelines above.</p>
              </div>
            </div>
          </div>

        </div>

        <br>

        <div class="card mb-4">
          <div class="card-header">Authors</div>
          <div class="card-body">
            <p class="card-text">Keith W. Hamilton, Christina Candeloro, Elle Saine, Brianna Lindsay, Stephen Saw, Vasilios Athans, Tiffany Lee, Robert Nietupski, Shawn Binkley, Sonal Patel, Brittany Hardek, Katherine Mersinger, Aiman Bandali, Hinal Patel, Amanda Binkley, Audrey Le Mahajan, Kathleen O. Degnan</p>
          </div>
        </div>
        <p>Last updated October 9, 2018</p>
      </article>
    </div>
  </div>

  <!-- FOOTER -->
  <footer class="footer-penn">
    Penn Medicine, Philadelphia, PA 800-789-PENN © 2020, The Trustees of the University of Pennsylvania
  </footer>

  <!-- Optional JavaScript -->
  <!-- jQuery first, then Popper.js, then Bootstrap JS -->
  <script src="https://code.jquery.com/jquery-3.5.1.slim.min.js" integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj" crossorigin="anonymous"></script>
  <script src="https://cdn.jsdelivr.net/npm/popper.js@1.16.0/dist/umd/popper.min.js" integrity="sha384-Q6E9RHvbIyZFJoft+2mJbHaEWldlvI9IOYy5n3zV9zzTtmI3UksdQRVvoxMfooAo" crossorigin="anonymous"></script>
  <script src="https://stackpath.bootstrapcdn.com/bootstrap/4.5.0/js/bootstrap.min.js" integrity="sha384-OgVRvuATP1z7JjHLkuOU7Xw704+h835Lr+6QL9UvYjZE3Ipu6Tp75j7Bh/kR0JKI" crossorigin="anonymous"></script>
  <!-- Font Awesome icon script -->
  <script>
    $(document).ready(function() {
      // Add minus icon for collapse element which is open by default
      $(".collapse.show").each(function() {
        $(this).prev(".card-header").find(".fa").addClass("fa-minus").removeClass("fa-plus");
      });

      // Toggle plus minus icon on show hide of collapse element
      $(".collapse").on('show.bs.collapse', function() {
        $(this).prev(".card-header").find(".fa").removeClass("fa-plus").addClass("fa-minus");
      }).on('hide.bs.collapse', function() {
        $(this).prev(".card-header").find(".fa").removeClass("fa-minus").addClass("fa-plus");
      });
    });
  </script>
</body></html>
